Literature DB >> 18353445

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.

Meindert Danhof1, Elizabeth C M de Lange, Oscar E Della Pasqua, Bart A Ploeger, Rob A Voskuyl.   

Abstract

The use of pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research is a promising approach that provides better understanding of drug efficacy and safety. It is applied to predict efficacy and safety in humans using in vitro bioassay and/or in vivo animal data. Current research in PK-PD modeling focuses on the development of mechanism-based models with improved extrapolation and prediction properties. A key element in mechanism-based PK-PD modeling is the explicit distinction between parameters for describing (i) drug-specific properties and (ii) biological system-specific properties. Mechanism-based PK-PD models contain specific expressions for the characterization of processes on the causal path between drug exposure and drug response. The different terms represent: target-site distribution, target binding and activation and transduction. Ultimately, mechanism-based PK-PD models will also characterize the interaction of the drug effect with disease processes and disease progression. In this review, the principles of mechanism-based PK-PD modeling are described and illustrated by recent applications.

Entities:  

Mesh:

Year:  2008        PMID: 18353445     DOI: 10.1016/j.tips.2008.01.007

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  81 in total

1.  Uricases as therapeutic agents to treat refractory gout: Current states and future directions.

Authors:  Xiaolan Yang; Yonghua Yuan; Chang-Guo Zhan; Fei Liao
Journal:  Drug Dev Res       Date:  2011-12-29       Impact factor: 4.360

Review 2.  Prediction of exposure-response relationships to support first-in-human study design.

Authors:  John P Gibbs
Journal:  AAPS J       Date:  2010-10-22       Impact factor: 4.009

Review 3.  The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG).

Authors:  Larry Tremaine; William Brian; Terrye DelMonte; Stephan Francke; Peter Groenen; Keith Johnson; Lei Li; Kimberly Pearson; Jean-Claude Marshall
Journal:  Pharmacogenomics       Date:  2015-11-30       Impact factor: 2.533

4.  Intermittent drug dosing intervals guided by the operational multiple dosing half lives for predictable plasma accumulation and fluctuation.

Authors:  Anita Grover; Leslie Z Benet
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-04-16       Impact factor: 2.745

5.  PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats.

Authors:  N Snelder; B A Ploeger; O Luttringer; D F Rigel; R L Webb; D Feldman; F Fu; M Beil; L Jin; D R Stanski; M Danhof
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

6.  Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections.

Authors:  Laura McEntee; Adam Johnson; Nicola Farrington; Jennifer Unsworth; Aaron Dane; Akash Jain; Nicole Cotroneo; Ian Critchley; David Melnick; Thomas Parr; Paul G Ambrose; Shampa Das; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

7.  Model-based prediction of the acute and long-term safety profile of naproxen in rats.

Authors:  Tarjinder Sahota; Ian Sanderson; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Pharmacol       Date:  2015-06-29       Impact factor: 8.739

Review 8.  The role of concentration-effect relationships in the assessment of QTc interval prolongation.

Authors:  Nicholas P France; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

9.  Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies.

Authors:  Maria Garcia-Cremades; Celine Pitou; Philip W Iversen; Iñaki F Troconiz
Journal:  AAPS J       Date:  2019-01-31       Impact factor: 4.009

10.  Development and application of a biomarker assay for determining the pharmacodynamic activity of an antagonist candidate biotherapeutic antibody to IL21R in whole blood.

Authors:  Maya Arai; Sadhana Jain; Amy A Weaver; Andrew A Hill; Yongjing Guo; Andrea G Bree; Michael F Smith; Scott W Allen; Edward R LaVallie; Deborah Young; Laird Bloom; Karissa Adkins; Margot O'Toole
Journal:  J Transl Med       Date:  2010-05-28       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.